LUGANO-GENEVA - Researchers have discovered a mechanism of resistance to checkpoint inhibitors and how to reverse it. The biomarker results from the IMvigor210 study are reported at the ESMO Immuno Oncology Congress 2017. (1)
Therapeutic antibodies that block the programmed death ligand 1(PD-L1) / programmed death 1 (PD-1) pathway, such as atezolizumab, can induce robust and durable responses in patients with various cancers, including metastatic bladder cancer. However, such responses occur only in a subset of patients.
“Understanding why the remaining 70–80% are resistant would enable us to target the mechanism with an additional drug and extend the benefits of checkpoint inhibitors to more patients,” said lead author Dr Sanjeev Mariathasan, Senior Scientist, Oncology Biomarker Department, Genentech, South San Francisco, US.
The IMvigor210 biomarker study investigated the drivers of efficacy and primary resistance to the anti-PD-L1 checkpoint inhibitor atezolizumab in 300 patients with bladder cancer. They used a combination of methods including immunohistochemistry, genome sequencing, and RNA expression.
The researchers found two drivers of efficacy and one driver of resistance. In terms of efficacy, tumours with the highest number of mutations – called a high mutation burden – were the most amenable to immunotherapy. Tumours that had T cells present in the tumour microenvironment were also more responsive to immunotherapy. Regarding resistance, tumours with high expression of the cytokine TGF-β tended to be unresponsive to immunotherapy.
When the researchers dug deeper into the mechanisms of resistance, they found three types of tumour microenvironment: 1) “immune desert” with few T cells (25% of bladder cancers); 2) “T cell excluded tumours” in which T cells are stuck in the stromal microenvironment and do not penetrate the tumour (50%); 3) “T cell inflamed tumours” where T cells have penetrated into the tumour (25%).
Mariathasan said that in “T cell excluded tumours”, the tumour may secrete a factor that builds a collagen-rich fortified wall around the tumours. The stromal microenvironment is like a Velcro that T cells stick to and do not enter the tumour. High expression of TGF-β and TGF-β-induced stromal genes in these excluded tumours were associated with non-responders, suggesting that these may help to fortify the tumour against T cell penetration.
The researchers then examined whether inhibiting TGF-β activity could improve the efficacy of atezolizumab. A mouse model with the “T cell excluded tumour” phenotype was used to compare four treatments: isotype antibody (control group), anti-PD-L1 alone, anti-TGF-β alone, and the combination of anti-TGF-β plus anti-PD-L1. In the combination group, TGF-β activity in stromal cells was reduced, T cells penetrated into the centre of the tumour, and the tumour reduced in size.
Mariathasan said: “This suggests that giving anti-TGF-β and anti-PD-L1 together can remodel the stromal microenvironment and allow T cells into the tumour. The ‘T cell excluded’ phenotype is common in other cancers such as lung, pancreatic and colorectal, so this combination therapy could be tested in a wider group.”
Commenting on the research, Professor Ignacio Melero, Senior Researcher, Centre for Applied Medical Research (CIMA), Pamplona, Spain, said: “Immunotherapy with PD-1/PD-L1 blockade is effective in a fraction of patients while it remains ineffective or suboptimal in most patients. It is key to identify the factors that impede more generalised benefit.”
“TGF-β is a soluble protein that is known to suppress immune responses through a variety of mechanisms,” continued Melero. “In this work, analysis of gene expression in clinical trial biopsies indicated that the gene signature of active TGF-β is in action in a fraction of bladder carcinoma patients who do not respond to PD-L1 blockade. In fact this seems to correlate with the inability of T killer lymphocytes to penetrate into the cancerous tissue. Moreover, experiments were undertaken in a transplantable breast cancer mouse model to see if TGF-β blockade is synergistic with PD-1/PD-L1 and it seems to be the case at least in that model.”
Regarding the potential clinical implications of the findings, Melero said: “TGF-β has been pursued as a pharmacological target in cancer therapy research for some time. Inhibitors come in the form of neutralising monoclonal antibodies and signalling inhibitors (SMAD inhibitors). These molecules are in clinical trials but have not yielded remarkable success because of efficacy and safety constraints. It is interesting to know that perhaps we can identify, by means of gene signatures, a fraction of patients in whom TGF-β is the dominant mechanism and focus on synergistic combinations blocking PD-1 and TGF-β simultaneously.”
When it comes to the need for further research, Melero said: “In bladder cancer it makes sense to design and implement a clinical trial that would select patients based on a TGF-β signature and treat them with an anti-TGF-β agent plus PD-1 or PD-L1 blockade. Better anti-TGF-β agents need to be developed for use combination with immunotherapy agents.”
George Coukos, Congress Co-Chair, Professor and Director, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland, said the research had two main implications: “First of all it explains why T cells are perhaps retained in the stroma and are not able to move into the tumour. Most importantly, it opens the door for improving therapeutic responses to PD-1/PD-L1 blockade by simultaneously targeting the TGF-β pathway.”
Coukos said a clinical study was needed combining PD-1 or PD-L1 blockade with TGF-β blockade in bladder cancer patients with the “T cell excluded tumour” phenotype, and then in other cancers with the same phenotype. “The T cell excluded tumours are the low hanging fruit in terms of clinical opportunity,” he said. “At the basic research level, we need to better understand why tumours establish this barrier to T cell infiltration, how it is mediated, what role the stromal fibroblasts play, and how the immune excluded phenotype gets orchestrated at the tumour site in order to escape immune recognition.”
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO Immuno Oncology Congress 2017
Official hashtag: #ESMOImmuno17
References
- Abstract 8O_PR ‘TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma‘ will be presented by Sanjeev Mariathasan during a Proffered Paper Session on Friday, 8 December, 08:30 to 10:30 (CET) in Room A. Annals of Oncology, Volume 28, 2017 Supplement 11.
Disclaimer
This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 17,000 members representing oncology professionals from 150 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.
Abstract 8O_PR
TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma
S. Mariathasan1, S.J. Turley1, D. Nickles1, A. Castiglioni1, K. Yuen1, Y. Wang1, K. Edward E. III1, H. Koeppen1, J.L. Astarita1, R. Cubas1, S. Jhunjhunwala1, Y. Yang1, Y. Şenbabaoğlu1, M. van der Heijden2, Y. Loriot3, I. Mellman1, D. Chen1, P. Hegde1, R. Bourgon1, T. Powles4
1Genentech, Inc., South San Francisco, CA, USA, 2Netherlands Cancer Institute, Amsterdam, Netherlands, 3Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France, 4Barts Cancer institute, St. Bartholomew's Hospital, London, UK
Background: Identifying determinants of response to cancer immunotherapy is critical for extending therapeutic benefit to more patients. Atezolizumab (anti–PD-L1) was approved in the US for the treatment of mUC based on the single-arm Phase II study IMvigor210 (NCT02108652). Here, we examined the biology underlying primary immune escape and responsiveness to anti–PD-L1 in tumor samples of participants of IMvigor210.
Methods: RECIST v1.1 objective response was a primary endpoint evaluated in all patients and in PD-L1 expression subgroups on tumor-infiltrating immune cells (SP142 IHC). Exploratory analyses in evaluable pre-treatment tissues included: (i) CD8 IHC analysis to define immune deserts, excluded and inflamed subtypes (ii) whole-transcriptome RNA sequencing to identify pathways associated with response and to perform Lund subtyping, (iii) targeted mutational profiling (FoundationOne) to estimate tumor mutation burden, and (iv) whole-exome sequencing to predict putative neoantigens. EMT6-grafted BALB/c mice treated with anti–TGF-β and/or anti–PD-L1 antibodies were evaluated for tumor growth inhibition.
Results: Response was associated with CD8+ T-effector gene expression and, to an even greater extent, high neoantigen or tumour mutation burden (TMB). Lack of response was associated with a signature of transforming growth factor β (TGF-β) signalling in fibroblasts, particularly in patients with CD8+ T cells that were excluded from the tumour parenchyma and instead found in the fibroblast- and collagen-rich peritumoural stroma. Using a mouse model that recapitulates this immune excluded phenotype, we found that therapeutic administration of a TGF-β blocking antibody together with anti–PD-L1 reduced TGF-β signalling in stromal cells, facilitated T cell penetration into the centre of the tumour, and provoked vigorous anti-tumour immunity and tumour regression.
Conclusions: Pre-existing T-cell immunity and TMB are associated with response to atezolizumab in mUC, whereas TGF-β signaling in the stroma is a negative indicator of response, especially in immune-excluded tumors, a common phenotype of mUC. Integration of these 3 independent biological features provides a strong basis for understanding clinical outcomes.
Legal entity responsible for the study: Genentech/Roche and academic institutions
Funding: Genentech/Roche
Disclosure: S. Mariathasan, S.J. Turley, D. Nickles, A. Castiglioni, K. Yuen, Y. Wang, K. Edward E. III, H. Koeppen, J.L. Astarita, R. Cubas, S. Jhunjhunwala, Y. Yang, Y. Şenbabaoğlu, I. Mellman, D. Chen, P. Hegde, R. Bourgon: Employee and stock owner of/by Genentench, Inc. M. van der Heijden: Served in a consultancy/advisory role for Roche, Astellas and AstraZeneca. Received grant from Astellas. Received reimbursement for patient care and data management of study subjects from Roche.
Y. Loriot: Received research funding from Sanofi. Consultancy or advisory role for Sanofi, Astellas, Janssen, Roche, AZ, MSD. Travel, accommodations and other expense: Astellas, Roche and MSD.
T. Powles: Served in a consultancy/advisory role, received research funding and honoraria from Merck, Roche, AstraZeneca, Pfizer, Novartis, Exelexis.
Keywords: anti-PD-L1, atezolizumab, biomarkers, bladder cancer